We are live on ! Find out more
PTHS

Pelthos Therapeutics
PTHS

5 hedge funds and large institutions have $59.6K invested in Pelthos Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.24% less ownership

Funds ownership: 0.38% → 0.15% (-0.24%)

79% less capital invested

Capital invested by funds: $290K → $59.6K (-$231K)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
APP
Avantax Planning Partners
Iowa
+$46K
2
TSS
Two Sigma Securities
New York
+$25.4K
3
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services
Minnesota
+$10.1K
4
TRCT
Tower Research Capital (TRC)
New York
+$244

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$265K
2
Citadel Advisors
Citadel Advisors
Florida
-$24.7K
3
UBS Group
UBS Group
Switzerland
-$246

PTHS Hedge Fund Activity: Q3 2024 in Review

5 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q3 2024, worth a combined $59.6K — down 79% from $290K a quarter earlier.

Fund positioning in PTHS was balanced in Q3 2024: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Avantax Planning Partners, opening a new position worth an estimated $46K. The largest seller was Anson Funds Management, exiting entirely with an estimated $265K sold.

  • 5 institutional investors held Pelthos Therapeutics (PTHS) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $59.6K of Pelthos Therapeutics stock for Q3 2024, down 79% quarter-over-quarter.
  • 3 funds opened new Pelthos Therapeutics positions in Q3 2024 and 3 closed out, a net change of 0 holders.
  • The largest Pelthos Therapeutics buyer in Q3 2024 was Avantax Planning Partners, an estimated $46K added.
  • The largest Pelthos Therapeutics seller in Q3 2024 was Anson Funds Management, an estimated $265K sold.

Based on aggregated 13F filings for Q3 2024.